Naglazyme Approved By Brazil’s National Health Surveillance Agency
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that ANVISA, Brazil’s National Health Surveillance Agency, has granted BioMarin marketing approval for Naglazyme(R) (galsulfase) for the treatment of patients with Mucopolysaccharidosis VI (MPS VI).
More: continued here
Filed under: Endocrinology on February 8th, 2009
You must be logged in to post a comment.